These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
319 related articles for article (PubMed ID: 21439312)
1. Targeting EGFR and VEGF(R) pathway cross-talk in tumor survival and angiogenesis. Larsen AK; Ouaret D; El Ouadrani K; Petitprez A Pharmacol Ther; 2011 Jul; 131(1):80-90. PubMed ID: 21439312 [TBL] [Abstract][Full Text] [Related]
2. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Tabernero J Mol Cancer Res; 2007 Mar; 5(3):203-20. PubMed ID: 17374728 [TBL] [Abstract][Full Text] [Related]
3. Resistance to epidermal growth factor receptor-targeted therapy. Morgillo F; Lee HY Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017 [TBL] [Abstract][Full Text] [Related]
4. Combined targeting of EGFR-dependent and VEGF-dependent pathways: rationale, preclinical studies and clinical applications. Tortora G; Ciardiello F; Gasparini G Nat Clin Pract Oncol; 2008 Sep; 5(9):521-30. PubMed ID: 18594498 [TBL] [Abstract][Full Text] [Related]
5. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. Hicklin DJ; Ellis LM J Clin Oncol; 2005 Feb; 23(5):1011-27. PubMed ID: 15585754 [TBL] [Abstract][Full Text] [Related]
6. Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. Viloria-Petit A; Crombet T; Jothy S; Hicklin D; Bohlen P; Schlaeppi JM; Rak J; Kerbel RS Cancer Res; 2001 Jul; 61(13):5090-101. PubMed ID: 11431346 [TBL] [Abstract][Full Text] [Related]
8. Cross-talk between G protein-coupled receptor and epidermal growth factor receptor signaling pathways contributes to growth and invasion of head and neck squamous cell carcinoma. Thomas SM; Bhola NE; Zhang Q; Contrucci SC; Wentzel AL; Freilino ML; Gooding WE; Siegfried JM; Chan DC; Grandis JR Cancer Res; 2006 Dec; 66(24):11831-9. PubMed ID: 17178880 [TBL] [Abstract][Full Text] [Related]
9. Drug development for cancer chemoprevention: focus on molecular targets. Johnson KA; Brown PH Semin Oncol; 2010 Aug; 37(4):345-58. PubMed ID: 20816505 [TBL] [Abstract][Full Text] [Related]
10. Growing tumor vessels: more than one way to skin a cat - implications for angiogenesis targeted cancer therapies. Leite de Oliveira R; Hamm A; Mazzone M Mol Aspects Med; 2011 Apr; 32(2):71-87. PubMed ID: 21540050 [TBL] [Abstract][Full Text] [Related]
11. Delta-like 4/Notch signaling and its therapeutic implications. Yan M; Plowman GD Clin Cancer Res; 2007 Dec; 13(24):7243-6. PubMed ID: 18094402 [TBL] [Abstract][Full Text] [Related]
12. The role of the EGFR signaling in tumor microenvironment. De Luca A; Carotenuto A; Rachiglio A; Gallo M; Maiello MR; Aldinucci D; Pinto A; Normanno N J Cell Physiol; 2008 Mar; 214(3):559-67. PubMed ID: 17894407 [TBL] [Abstract][Full Text] [Related]
15. Inhibition of vascular endothelial growth factor (VEGF) as a novel approach for cancer therapy. Wood JM Medicina (B Aires); 2000; 60 Suppl 2():41-7. PubMed ID: 11188930 [TBL] [Abstract][Full Text] [Related]
16. Different cascades in the signaling pathway of two vascular endothelial growth factor (VEGF) receptors for the VEGF-mediated murine hepatocellular carcinoma development. Yoshiji H; Noguchi R; Kuriyama S; Yoshii J; Ikenaka Y; Yanase K; Namisaki T; Kitade M; Yamazaki M; Uemura M; Fukui H Oncol Rep; 2005 May; 13(5):853-7. PubMed ID: 15809749 [TBL] [Abstract][Full Text] [Related]
17. Vascular endothelial growth factor is an in vivo survival factor for tumor endothelium in a murine model of colorectal carcinoma liver metastases. Bruns CJ; Liu W; Davis DW; Shaheen RM; McConkey DJ; Wilson MR; Bucana CD; Hicklin DJ; Ellis LM Cancer; 2000 Aug; 89(3):488-99. PubMed ID: 10931447 [TBL] [Abstract][Full Text] [Related]